ASCO GU 2024
ASCO GU 2024 Prostate Cancer
- ASCO GU 2024: The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy
- ASCO GU 2024: Assessing the Clinical Utility of Rapid Post-Therapy Whole-Body Digital SPECT/CT in Evaluating Early Treatment Response of 177Lu-PSMA-617 Treatment
- ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15)
- ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC
- ASCO GU 2024: Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC
ASCO GU 2024 Bladder Cancer
- ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery
- ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)
- ASCO GU 2024: Catalysts for Change: Patient Advocacy’s Role in Drug Shortages
- ASCO GU 2024: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin with or Without Pembrolizumab for High-Risk Non–muscle-Invasive Bladder Cancer That Persists/recurs After BCG Induction
- ASCO GU 2024: Approach to the Platinum Shortage from a Community Oncologist Perspective
ASCO GU 2024 Kidney Cancer
- ASCO GU 2024: Update on Biomarkers in Renal Cell Carcinoma
- ASCO GU 2024: Management of Non-Clear Cell Renal Cell Carcinoma
- ASCO GU 2024: Genetic Testing in RCC: Who, When, and How?
- ASCO GU 2024: The Emergent Role of Theranostics in Renal Cell Carcinoma
- ASCO GU 2024: Belzutifan Versus Everolimus in Participants With Previously Treated Advanced Renal Cell Carcinoma: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study
ASCO GU 2024 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2024: Utility of Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Disease Monitoring in Patients with Non-Seminomatous Germ-Cell Tumor
- ASCO GU 2024: Longitudinal Tumor-Informed ctDNA Assay and Patient Outcomes in Testicular Cancer
- ASCO GU 2024: Evaluating Prognostic Models for Stage I Seminoma Within the Randomised Trial of Imaging and Surveillance in Seminoma Testis (TRISST)
- ASCO GU 2024: Cabozantinib plus Atezolizumab in Locally Advanced/metastatic Adrenocortical Carcinoma: Results from a Multi-Cohort Basket Phase II Trial, CABATEN/GETNE-T1914
- ASCO GU 2024: Survivorship Issues Beyond 2 Years After Treatment in Testicular Germ Cell Tumors: Experience from a Large Center in the United Kingdom
ASCO GU 2024 Upper Tract Urothelial Carcinoma
- ASCO GU 2024: Neoadjuvant Combined Chemotherapy and Immunotherapy for Upper Tract Urothelial Carcinoma: Preliminary Results From a Phase II Study
- ASCO GU 2024: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer: Updated Results
- ASCO GU 2024: Sequential Endoluminal Gemcitabine and Docetaxel vs BCG for the Treatment of High-grade UTUC
- ASCO GU 2024: A Phase II Study of Tislelizumab Monotherapy as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma
- ASCO GU 2024: FGFR3 Mutated Urothelial Carcinoma of Bladder or Upper Tract: A Comparative Genomic Landscape Study
ASCO GU 2024 Press Releases
- Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024
- Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
- Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
- Combination of Cabozantinib and Atezolizumab Offers Hope for Patients with Type of Advanced Prostate Cancer with Poor Prognosis
- Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium